mAB 4-8
A human monoclonal anti-NTD (SARS-CoV-2 Spike) antibody.
General information
mAB 4-8 is a human monoclonal antibody targeting SARS-CoV-2 Spike N-terminal domain glycan-free site (Cerutti et al., 2021). It neutralized SARS-CoV-2 live virus with an IC50 of 0.009 μg/ml in vitro (Liu et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Spike protein Animal model In vitro Antibody |
in vitro binding assay; Vero cells; golden Syrian hamsters; SARS-CoV-2 strain USA-WA1/2020 | 42.78 | Neutralized SARS-CoV-2 live virus with an IC50 of 0.009 μg/ml in vitro. It neutralized a Spike-pseudotyped virus, as well. |
Jul/22/2020 |
|
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Spike protein Cryo-EM Crystallization Biophysical assay In vitro Antibody |
in vitro biophysical assay; crystallization; cryo-EM; Vero E6; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 live virus | 15.92 | Targets a SARS-CoV-2 Spike protein N-terminal domain supersite. The site is glycan-free and electropositive and is recognized by multiple neutralizing antibodies (the epitopes are overlapping but the recognition might differ). |
Mar/12/2021 |
